Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Kim A. Papp; James G. Krueger; Steven R. Feldman; Richard G. Langley; Diamant Thaci; Hideshi Torii; Stephen Tyring; Robert Wolk; Annie Gardner; Charles Mebus; Huaming Tan; Yingchun Luo; Pankaj Gupta; Lotus Mallbris; Svitlana Tatulych

doi:10.1016/j.jaad.2016.01.013

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Kim A. Papp, James G. Krueger, Steven R. Feldman, Richard G. Langley, Diamant Thaci, Hideshi Torii, Stephen Tyring, Robert Wolk, Annie Gardner, Charles Mebus, Huaming Tan, Yingchun Luo, Pankaj Gupta, Lotus Mallbris, Svitlana Tatulych

Inernational Relations Division

Research output: Contribution to journal › Article › peer-review

135 Citations (Scopus)

Original language	English
Pages (from-to)	841-850
Number of pages	10
Journal	Journal of the American Academy of Dermatology
Volume	74
Issue number	5
DOIs	https://doi.org/10.1016/j.jaad.2016.01.013
Publication status	Published - May 1 2016

ASJC Scopus Subject Areas

Dermatology

Keywords

Janus kinase inhibitor
efficacy
long-term
psoriasis
randomized controlled trial
safety
tofacitinib

Access to Document

10.1016/j.jaad.2016.01.013

Fingerprint

Dive into the research topics of 'Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study'. Together they form a unique fingerprint.

Cite this

Papp, K. A., Krueger, J. G., Feldman, S. R., Langley, R. G., Thaci, D., Torii, H., Tyring, S., Wolk, R., Gardner, A., Mebus, C., Tan, H., Luo, Y., Gupta, P., Mallbris, L., & Tatulych, S. (2016). Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. Journal of the American Academy of Dermatology, 74(5), 841-850. https://doi.org/10.1016/j.jaad.2016.01.013

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. / Papp, Kim A.; Krueger, James G.; Feldman, Steven R. et al.
In: Journal of the American Academy of Dermatology, Vol. 74, No. 5, 01.05.2016, p. 841-850.

Research output: Contribution to journal › Article › peer-review

Papp, KA, Krueger, JG, Feldman, SR, Langley, RG, Thaci, D, Torii, H, Tyring, S, Wolk, R, Gardner, A, Mebus, C, Tan, H, Luo, Y, Gupta, P, Mallbris, L & Tatulych, S 2016, 'Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study', Journal of the American Academy of Dermatology, vol. 74, no. 5, pp. 841-850. https://doi.org/10.1016/j.jaad.2016.01.013

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. Journal of the American Academy of Dermatology. 2016 May 1;74(5):841-850. doi: 10.1016/j.jaad.2016.01.013

@article{b60b819faa8548a99e387519aff84d19,

title = "Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study",

keywords = "Janus kinase inhibitor, efficacy, long-term, psoriasis, randomized controlled trial, safety, tofacitinib",

author = "Papp, {Kim A.} and Krueger, {James G.} and Feldman, {Steven R.} and Langley, {Richard G.} and Diamant Thaci and Hideshi Torii and Stephen Tyring and Robert Wolk and Annie Gardner and Charles Mebus and Huaming Tan and Yingchun Luo and Pankaj Gupta and Lotus Mallbris and Svitlana Tatulych",

note = "Publisher Copyright: {\textcopyright} 2016 American Academy of Dermatology, Inc.",

year = "2016",

month = may,

day = "1",

doi = "10.1016/j.jaad.2016.01.013",

language = "English",

volume = "74",

pages = "841--850",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis

T2 - Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

AU - Papp, Kim A.

AU - Krueger, James G.

AU - Feldman, Steven R.

AU - Langley, Richard G.

AU - Thaci, Diamant

AU - Torii, Hideshi

AU - Tyring, Stephen

AU - Wolk, Robert

AU - Gardner, Annie

AU - Mebus, Charles

AU - Tan, Huaming

AU - Luo, Yingchun

AU - Gupta, Pankaj

AU - Mallbris, Lotus

AU - Tatulych, Svitlana

PY - 2016/5/1

Y1 - 2016/5/1

KW - Janus kinase inhibitor

KW - efficacy

KW - long-term

KW - psoriasis

KW - randomized controlled trial

KW - safety

KW - tofacitinib

UR - http://www.scopus.com/inward/record.url?scp=84963632371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963632371&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2016.01.013

DO - 10.1016/j.jaad.2016.01.013

M3 - Article

C2 - 26899199

AN - SCOPUS:84963632371

SN - 0190-9622

VL - 74

SP - 841

EP - 850

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 5

ER -

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this